New Delhi: Ranbaxy Laboratories said on Friday it has transferred its new drug discovery research unit (NDDR) to Daiichi Sankyo India Pharma as part of strengthening global research and development structure of the group.
“The new organisation RCI, based in Gurgaon, will play a key role in the group’s global drug discovery research,” Ranbaxy said in a statement.
As part of the transfer, Ranbaxy’s new drug discovery research will be renamed as Daiichi Sankyo Life Science Research Center (RCI), which will be under Daiichi Sankyo India Pharma.
“With the transfer of the NDDR into the Daichii Sankyo Group’s pharmaceutical R&D organisation, we will further strengthen our integrated global research capabilities through the addition of talented researchers,” Daiichi Sankyo president and CEO Joji Nakayama said.
Ranbaxy and Daiichi Sankyo group have cooperated in research and development segment since 2008 when the former integrated with Daiichi Sankyo.
Ranbaxy’s NDDR was established in 1994 and has been involved in high level synthetic chemical research to come up with new drugs.
“The NDDR group offers significant skill sets in drug discovery, that would now integrate and perform more effectively with the new drug R&D structure of Daiichi Sankyo,” Ranbaxy CEO and managing director Atul Sobti said.
Meanwhile, RCI will continue to support the research programmes on dengue and tuberculosis that NDDR was working on in alliance with the Department of Biotechnology, government of India, the company said.
Ranbaxy that will imitate the hybrid business model followed by the Daiichi group, will primarily focus on generic medicine research both for itself and its parent firm while the new drug discovery programme will be taken up by Daiichi Sankyo.
Ranbaxy became a subsidiary of Daiichi Sankyo Group in 2008 after Japan’s third largest drug maker bought a majority stake in the company for Rs22,000 crore.
Shares of Ranbaxy were trading at Rs458.60 on late afternoon trade on Bombay Stock Exchange, down 0.53% from its previous close.